RE:Orphan drug pricingjfm1330 wrote: Those who think Trogarzo (Ibalizumab) will be expensive at $118,000 per year. Look at Hemlibra (Emicizumab) for difficult to treat hemophilia patients. Approved in November 2017, the WAC price is $482,000 per year. Four times the price of Trogarzo and it's also a monoclonal antibody, so similar price to manufacture. The only difference is that it is weekly subcutaneous self injection and the dose is much lower, so less antibody to manufacture per dose and no extra cost for I.V. injections under medical supervision.
All that to say that in comparison to this drug, Trogarzo looks cheap. It gives perspective. By the way, peak sales for this new drug are expected to reach $5 billions per year. So you can sell at very high price and still have a fairly good number of patients.
https://formularyjournal.modernmedicine.com/formulary-journal/news/top-5-pipeline-drugs-2018
https://www.biopharmadive.com/news/hemlibra-europe-approval-roche-hemophilia-label/518019/
*
Average Orphan Drug Cost to Patients $140,443 in 2016;
Median Orphan Drug Cost $83,883.
EvaluatePharma® estimates that the average cost per patient per
year in 2016 for an orphan drug was $140,443 versus $27,756 for a
non-orphan drug.
So according to this report, Trogarzo is $22 000 cheaper than the average.
https://info.evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf